Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

Table 10. Other Clinical Predictors of Disease Response or Survival


Prognostic Factor

Studies Indicating an Association and Quality

Strength of Association with Tumor Response

Strength of Association with Survival

Performance status

Poor vs. good performance status at baseline

Heinrich, et al., 2003
(quality = 6/6)47

Verweij, et al., 2004
(quality = 6/6)49

HR:  1.57 (1.18-2.1)
p = 0.0022*

No significant relationship

HR:  2.8 (1.57-5.02)
p = 0.0005*

Dose of imatinib

600 mg vs. 400 mg dose

Heinrich, et al., 2003
(quality = 6/6)47

HR:  0.57 (0.36-0.91) 
p = 0.018*



Elevated creatinine at baseline vs. not elevated

Heinrich, et al., 2003
(quality = 6/6)47


HR:  2.9 (0.86-9.80)
p = 0.0866*

Prior chemotherapy

Prior chemotherapy vs. no prior chemotherapy

Heinrich, et al., 2003
(quality = 6/6)47


HR:  2.6 (0.98-7.06) 
p = 0.0558*

Abbreviations:  PET = FDG positive emission tomography; CT = computed tomography; TTP = time to progression; OS = overall survival; EFS = event free survival; HR = hazard ratio; RECIST = RECIST response criteria—go to Table 2; NS = not significant

*In this study hazard rations greater than one are predictive of poorer prognosis.

Return to Document

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care